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Abstract
Background—Botulism is a rare, life-threatening paralytic illness. Equine-derived heptavalent 
botulinum antitoxin (HBAT), the only currently available treatment for noninfant botulism in the 
United States, was licensed in 2013. No reports have systematically examined safety and clinical 
benefit of HBAT among botulism patients.
Methods—From March 2010 through March 2013, we collected data prospectively and through 
medical record reviews of patients with confirmed or suspected botulism who were treated with 
HBAT under an expanded-access Investigational New Drug program.
Results—Among 249 HBAT-treated patients, 1 (<1%) child experienced an HBAT-related 
serious adverse event (hemodynamic instability characterized by bradycardia, tachycardia, and 
asystole); 22 (9%) patients experienced 38 nonserious adverse events reported by physicians to be 
HBAT related. Twelve (5%) deaths occurred; all were determined to be likely unrelated to HBAT. 
Among 104 (42%) patients with confirmed botulism, those treated early (≤2 days) spent fewer 
days in the hospital (median, 15 vs 25 days; P < .01) and intensive care (10 vs 17 days; P = .04) 
than those treated later. Improvements in any botulism sign/symptom were detected a median of 
2.4 days and in muscle strength a median of 4.8 days after HBAT.
Conclusions—HBAT was safe and provided clinical benefit in treated patients. HBAT 
administration within 2 days of symptom onset was associated with shorter hospital and intensive 
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care stays. These results highlight the importance of maintaining clinical suspicion for botulism 
among patients presenting with paralytic illness to facilitate early HBAT treatment before 
laboratory confirmation might be available. Clinical consultation and, if indicated, HBAT release, 
are available to clinicians 24/7 through their state health department in conjunction with CDC.
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Botulism is a rare illness caused by toxin produced by Clostridium botulinum. is potent 
toxin binds irreversibly to nerve endings at neuromuscular junctions, causing varying 
degrees of paralysis, respiratory failure, and even death [1]. Botulinum antitoxin is the only 
specific therapy for botulism. It binds circulating botulinum toxin and halts illness 
progression, but does not reverse deficits that have already developed. Because laboratory 
confirmation takes time, during which neurologic deficits may progress, and because it may 
not confirm all botulism illnesses, antitoxin is administered empirically as soon as possible 
after clinical suspicion is raised. Botulism occurs sporadically each year and outbreaks may 
occur; botulism cases and outbreaks are public health emergencies that require a vigorous 
response to ensure treatment of affected persons and investigation of the source to prevent 
further illnesses [2]. Intentional exposures, such as in a bioterror event, could cause 
thousands of illnesses.
Exposure to botulinum toxin occurs through several routes, including ingestion of preformed 
toxin in foods, toxin produced by germinating botulinum spores in colonized wounds or the 
intestinal tract, and injection of high concentrations of botulinum toxin for therapeutic 
purposes. Infant botulism occurs due to production of toxin by C. botulinum colonizing the 
immature infant gastrointestinal system and is treated in the United States with BabyBIG®, a 
human immunoglobulin approved for infant botulism caused by toxin types A and B [3]. 
Noninfant botulism is treated with equine-derived antitoxin, produced by hyperimmunizing 
horses with botulinum toxin. There have been prior formulations of equine botulinum 
antitoxin available through the Centers for Disease Control and Prevention (CDC) for 
noninfant persons in the United States since the 1960s. In 2010, the first heptavalent 
formulation capable of neutralizing toxin serotypes (A, B, C, D, E, F, G), although still 
investigational at the time, replaced previous formulations. To ensure continued availability 
of antitoxin in the United States, CDC implemented an expanded-access Investigational New 
Drug program (“compassionate use” IND) starting in March 2010. As a secondary goal, the 
IND program enabled collection of data on safety and clinical benefit. In 2013, heptavalent 
botulinum antitoxin (HBAT, also known by its licensed name BAT) was approved by the US 
Food and Drug Administration (FDA) based on the Animal Efficacy Rule, under which 
products treating rare illnesses that are not ethical or feasible to be studied using randomized 
controlled trials may be approved based on efficacy demonstrated in animals [4]. Safety and 
clinical outcomes data on HBAT in ill patients from the IND were part of the supportive data 
for licensure of HBAT but have not previously been published. Data on previous antitoxin 
formulations are limited and HBAT is a new formulation. Post-licensure data collection by 
the manufacturer, Cangene Corporation, as part of its FDA-required post-marketing 
commitments, has not yet completed and therefore, data not available for inclusion in or as a 
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companion to this article. We present the first report on clinical use of HBAT for suspected 
and confirmed botulism during the CDC IND program.
METHODS
The CDC, working with state and local health departments, provides clinical consultation 
and antitoxin release 24 hours a day for all noninfant patients who may have botulism in the 
United States (antitoxin for treatment of infant botulism is available by contacting the 
California Department of Public Health). During the IND period of March 2010 through 
March 2013 and for 4 patients treated in 2008–2009, CDC provided investigational HBAT 
for treatment of patients under a CDC Institutional Review Board–approved protocol. The 
protocol contained information about HBAT, including case report forms (CRFs), 
instructions on obtaining informed consent, HBAT administration, and monitoring and 
reporting of adverse events (AEs), including serious adverse events (SAEs). Skin sensitivity 
testing was optional. The HBAT regimen for adults was a single dose of 1 vial whereas the 
pediatric dose was weight-based; the infant dose during the early phase of the IND was 20% 
of the adult dose. HBAT is formulated to meet a minimum potency level for each antitoxin 
type expressed as units based on mouse neutralization assay: A (4500 U), B (3300 U), C 
(3000 U), D (600 U), E (5100 U), F (3000 U), G (600 U) [5]. The half-life of one vial of 
HBAT ranges from 7.51 hours to 34.20 hours depending on the antitoxin serotype [5].
Definitions and Data Collection
Baseline clinical information was collected verbally at the time of HBAT consultation and, 
in keeping with HBAT investigational status, physicians were required to comply with the 
protocol and complete CRFs assessing AEs from HBAT through written reports to CDC. 
CRF data were obtained soon after HBAT administration and upon patient discharge. CDC 
systematically contacted hospital staff during patients’ hospitalizations to enhance CRF 
completion. Medical records were obtained from hospitals to abstract: (1) dates of symptom 
onset and improvement, hospital admissions, transfers, and discharges and dates of 
tracheostomy placement; (2) durations of mechanical ventilation and hospitalization in 
intensive care settings; and (3) clinical deficits at time of acute care discharge and location to 
which a patient was discharged.
AEs were defined as any untoward medical occurrence related to HBAT per FDA’s IND 
safety reporting regulations [6]. Physicians reported AEs related to HBAT by completing 
and returning CRFs that inquired about (1) occurrence or absence of AEs including fever, 
chills/rigors, rash, urticaria, edema, urinary retention, anaphylaxis, serum sickness, and other 
reactions; (2) AE duration and timing; (3) any treatment of AEs; and (4) sequelae from AEs. 
SAEs, including serious unexpected suspected adverse reactions, were defined per FDA IND 
safety reporting regulations [6]. Information on patient clinical outcomes (eg, survival) was 
obtained through patient discharge from acute hospitalization and inpatient rehabilitation. 
Because equine antitoxins carry a risk of hypersensitivity including anaphylaxis and serum 
sickness, skin testing results and the occurrence of AEs to HBAT administration were 
evaluated when data on skin sensitivity testing were available. Results of laboratory testing 
were obtained directly from public health reference laboratories. We used the Council of 
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State and Territorial Epidemiologists definition of confirmed botulism: illness clinically-
compatible with botulism and that is laboratory-confirmed or epidemiologically-linked to a 
laboratory-confirmed case [7]. For analysis of duration of hospitalization, intensive care unit 
(ICU) stay, and mechanical ventilation, early treatment was defined as HBAT administration 
within 2 days of symptom onset and later treatment as >2 days from symptom onset.
Data Analysis
Safety was assessed among all HBAT-treated patients, irrespective of botulism confirmation. 
SAEs, including all deaths reported by physicians regardless of botulism confirmation status 
or physician-reported association with HBAT, were assessed by the CDC principal 
investigator for relatedness to HBAT by reviewing patients’ medical records and 
correspondence with physicians. To assess clinical benefit of HBAT, only confirmed 
botulism cases were further analyzed. Median durations of hospitalization, ICU stay, and 
mechanical ventilation were calculated for patients treated early (≤2 days of symptom onset) 
and those treated later (>2 days from symptom onset). Differences were assessed by 
Wilcoxon rank-sum test. Patients who died during acute care were excluded to avoid biasing 
calculations of median durations of hospitalization, ICU stay, and mechanical ventilation. 
Kaplan-Meier curves with log-rank test were generated to compare durations of 
hospitalization, ICU stay, and mechanical ventilation between patients treated early and 
those treated later. The percentage of botulism-confirmed patients who died was compared 
between patients treated with HBAT early and those treated later, with difference assessed 
by Fisher exact test.
Timing of HBAT administration from symptom onset and time to first documented 
improvement in any signs or symptoms of botulism (including extraocular palsy, ptosis, 
pupillary signs, impaired gag reflex, blurred vision, diplopia, dysphagia, slurred speech, 
subjective strength improvement) was assessed by simple linear regression. Patients with 
reported improvement before HBAT administration were excluded from linear regression 
analysis. All statistical analyses were done using SAS version 9.3 (SAS Institute). Two-sided 
P values <.05 were considered statistically significant.
RESULTS
A total of 249 persons aged 10 days–88 years (median, 46 years) were treated with HBAT 
(Table 1). Of these, 17 (7%) were children (median, 6 years; range, 10 days–17 years). None 
of the 249 treated patients were pregnant or breastfeeding. Botulism was laboratory or 
epidemiologically confirmed for 104 (42%) patients. Confirmed cases were caused by toxin 
types A (74%), Ab (1%), B (7%), E (7%), F (4%), and indeterminate type (8%) with 
exposure occurring via all naturally occurring transmission routes.
Safety of Heptavalent Botulinum Antitoxin
Among 249 patients, 23 (9%) experienced at least 1 AE reported by physicians as HBAT-
related: 22 (9%) patients experienced 38 nonserious AEs and 1 patient experienced an 
HBAT-related SAE (Table 2). No patients experienced anaphylaxis. The single case of serum 
sickness occurred in a 64-year-old man, which occurred 11 days after HBAT administration 
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and physician-reported as mild, self-limited serum sickness characterized by myalgia and 
arthralgia treated with ibuprofen; the principal investigator also determined it as not serious 
[8].
One HBAT-related SAE occurred in a 10-year-old boy weighing 29 kg who was reported to 
have experienced bradycardia leading to asystole approximately 90 minutes after initiation 
of HBAT infusion; the lowest observed heart rate immediately before asystole was 10–15 
beats per minute [bpm]). Pediatric administration instructions at the time recommended 
starting the infusion at a rate of 0.1–0.5 mL/min for at least 30 minutes, then increasing the 
rate to 0.2–1 mL/min for the subsequent 30 minutes and thereafter. The treating physician 
reported an initial infusion rate of 0.1 mL/min for 30 minutes. The infusion rate thereafter 
was not reported, including during the time at which the patient experienced bradycardia and 
asystole. The administration was halted when asystole occurred, epinephrine was 
administered, and chest compressions performed. Administration was restarted after a pause 
of approximately 5 minutes. At this time the patient was tachycardic (140 bpm), possibly in 
consequence of receiving epinephrine, but regained normal cardiac rhythm. No other 
abnormalities were observed until approximately 30 minutes after the infusion had been 
restarted, when the patient abruptly experienced a second bradycardic episode (30–40 bpm) 
and HBAT administration was altogether stopped; an estimated 73% of the intended dose 
(40 ml of 55 ml) was administered overall.
A total of 12 deaths (5%) were reported; none were related to HBAT by either physician 
report or by CDC principal investigator review (Table 3). Characteristics of patients who 
died and cause of death as determined by CDC principal investigator review are listed in 
Table 3.
Most reported, HBAT-related AEs were nonserious and included fever (n = 9 [4%]), rash (n 
= 4 [2%]), and chills (n = 3 [1%]) (Table 2) and resolved with medications such as 
acetaminophen, diphenhydramine, and methylprednisolone. Although skin sensitivity testing 
was not required, it was conducted for 33 patients; all but 1 had negative skin test results and 
no resulting allergic reaction with HBAT administration. The 1 patient with a positive skin 
test prior to HBAT treatment experienced facial swelling and facial and truncal rash 1 day 
after HBAT treatment and nausea, chest pressure, and “jitteriness” 2 days later. Information 
is not available on whether the patient was pretreated for allergy before HBAT 
administration. The patient recovered without sequelae after treatment with 
diphenhydramine, methylprednisolone, and ondansetron.
Three adults each received 2 HBAT doses, from 4 to 34 days apart: 2 had a second episode 
of botulism and 1 was re-treated off-protocol due to lack of clinical improvement. No AEs 
were reported. An additional 3 HBAT-treated adults had a prior history of botulism for 
which they were treated with an older, previously available antitoxin formulation from 4 to 8 
years before HBAT treatment; they also did not experience any AEs.
Clinical Outcomes and Timing of Heptavalent Botulinum Antitoxin Administration
Among 104 botulism-confirmed patients, all 33 patients treated within 2 days of symptom 
onset (early treatment) survived while 64 of 71 (90%) patients treated later survived; this 
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difference was not statistically significant. Early HBAT treatment was associated with 
statistically significant shorter hospital (median, 15 vs 25 days; P < .01) and ICU (10 vs 17 
days; P = .04) stays compared with later HBAT treatment (Table 4; Figure 1). Simple linear 
regression indicated that improvement in any of the botulism signs or symptoms occurred 
2.4 days (95% confidence interval [CI], 1.6–3.1) after HBAT administration, while strength 
improvement occurred 4.8 days (95% CI, 2.5–7.1) after administration, irrespective of 
timing of administration (regression coefficients in both models were 1.0 [95% CIs, .8–1.2 
and .4–1.6]).
Intubation followed HBAT administration in 10 (14%) patients with median time to 
intubation of <1 day (range, <1 to 3 days); these patients were treated with HBAT a median 
of 4 days from symptom onset (range, 1–11 days). Of 104 botulism-confirmed patients, 73 
(70%) required mechanical ventilation. Disposition of patients were as follows: 61 (59%) 
were discharged home, 32 (31%) were discharged to a long-term acute care facility, 7 (7%) 
were discharged to a skilled nursing facility/nursing home, and 1 (1%) left against medical 
advice. ree patients (3%) died during acute hospitalization. Of 73 patients who received 
mechanical ventilation, 54 (74%) underwent tracheostomy. Most (88, 89%) botulism-
confirmed patients had residual disability upon discharge consisting of neurological deficits 
and/or persistent subjective weakness while 11 (11%) were reported as having no residual 
disability upon discharge among patients for whom data were available. The percentage of 
patients with residual disability at discharge did not differ significantly between patients 
treated with HBAT early (91%) and those treated later (88%).
DISCUSSION
Since 2010, HBAT has been the only antitoxin available in the United States for treatment of 
noninfant botulism, capable of neutralizing toxin types (A, B, C, D, E, F, G). Our data are 
the first published on the safety and clinical outcomes associated with HBAT administration 
among patients with suspected and confirmed botulism. For most patients, HBAT was well-
tolerated: 9% developed any HBAT-related AE and 1 patient (<1%) developed a related 
SAE. No deaths related to HBAT were reported. We found that early HBAT administration 
was associated with shorter hospital and ICU stays among patients with confirmed botulism. 
These results highlight the importance of early treatment of suspected botulism with HBAT, 
usually before laboratory confirmation is available. Around-the-clock clinical consultation 
and HBAT release are available to clinicians through their state health department in 
conjunction with CDC.
Mortality from botulism decreased from approximately 60% to <5% over the course of the 
20th century in the United States, attributed to advances in critical care, specifically 
mechanical ventilation [2, 9–12]. Outbreak investigation reports, case reports, case series, 
and animal studies suggested that early administration of previously available botulinum 
antitoxins improved morbidity and mortality [12]. Our findings suggest the same is true for 
HBAT: we found that early HBAT administration was associated with shorter hospitalization 
and intensive care. Additionally, we observed no deaths among patients treated early, 
whereas 10% of patients who received HBAT >2 days after symptom onset died.
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The observation that early HBAT administration was associated with reduced duration of 
hospitalization and intensive care is consistent with the mechanism of action of HBAT, 
neutralization of free-circulating toxin, preventing toxin from exerting its action in 
neuromuscular junctions and preventing further symptom progression [13, 14]. Furthermore, 
our findings illustrate the expected clinical benefit of HBAT is limited to halting progression 
of botulism and not speeding recovery. Our data show that improvements in signs and 
symptoms and in strengths occurred after HBAT administration. However, time to 
improvement of any sign or symptom (eg, improvement in cranial nerve symptoms) appears 
to be similar regardless of the timing of HBAT administration following symptom onset. 
While there is as yet no rapid point-of-care diagnostic test for botulism and even if one were 
to become available, HBAT should be considered upon clinical suspicion based on signs and 
symptoms and, if available, exposure history, as early treatment is most beneficial in 
preventing further disease progression [15]. Treatment should not be contingent on 
laboratory or other diagnostic testing (eg, electromyography) due to delay in conducting 
such evaluations and their limitations [15, 16]. us, HBAT should be administered as soon as 
possible. Even if treatment were inadvertently delayed, HBAT may still be of clinical benefit 
given the potential that prolonged toxemia may be present [17]. Clinicians suspecting 
botulism should immediately contact their state health department’s emergency telephone 
number for consultation and referral to CDC’s Botulism Clinical Consultation Service, 
which provides review of clinical presentation and, if indicated, releases an emergency 
shipment of HBAT for patient treatment.
Reports on botulinum antitoxin products employed in previous decades cite rates of 
anaphylaxis and serum sickness of 1–2% and 1–4%, respectively; rates varied with number 
of vials administered [18–21]. With HBAT, we observed anaphylaxis and serum sickness 
rates of 0% and <1%, respectively. Despeciation of HBAT involves removal of equine-
derived Fc segments of the equine immunoglobulin G, resulting in purified F(ab′)2 and F(ab
′)2,-related immune globulin fragments and purification [22]. Whether this contributes to 
lower allergenicity is uncertain. Historically, for older equine-derived botulinum antitoxin 
formulations, skin sensitivity testing before administration was recommended [23, 24]. 
Although skin testing was predictive of an allergic reaction in a single patient in our 
analysis, other studies suggest that the positive predictive value is low [18, 19, 25]. In 
clinical trials of 56 healthy adults, despite negative skin testing with horse dander 
immunoglobulin E and HBAT before HBAT administration, 2 subjects experienced 
hypersensitivity reactions including urticaria [4]. Given concerns about its accuracy, 
sensitivity testing, which can delay HBAT administration, is not recommended. HBAT 
should be administered in a setting where hypersensitivity reactions, should they occur, can 
be identified and treated.
The seven botulinum toxin serotypes A–G were described between 1919 and 1970. 
Recently, reports of new toxin types have been published, including a novel toxin 
subsequently shown to be hybrid type A/F fully neutralized by HBAT [26, 27], and a novel 
toxin identified and assembled from the published gene sequence of a C. botulinum isolate 
[28]. New botulinum toxins of clinical significance might be discovered. Preparedness 
requires careful laboratory investigation of all suspected botulism cases and research and 
development of new countermeasures.
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Given clinical trial data on HBAT were limited to 2 phase 1 trials in 56 healthy adult 
subjects, our data provide the first assessment of information derived from clinical use of 
HBAT to treat patients with suspected or confirmed botulism. However, our investigation has 
several limitations. Because HBAT was provided under expanded-access IND with the 
primary objective of providing treatment for life-threatening disease, it was not a clinical 
trial and no comparison group without treatment is available. Efficacy is typically 
demonstrated by prospective randomized controlled clinical trials and could not be 
definitively drawn from clinical information collected from only HBAT-treated patients. Our 
data collection was dependent on physicians completing and returning CRFs. However, 
through our active follow-up process, the return rate of CRFs containing safety and clinical 
outcome information was 93%, which was historically challenging to achieve. With the 
exception of deaths and SAEs, nonserious AEs were physician-reported and not further 
investigated. Deaths that occurred after hospital discharge and completion of our follow-up 
may not have been reported to us for further evaluation. Other confounding factors may have 
contributed to clinical outcomes such as toxin exposure level, individual host factors, and 
progression of botulism symptoms and neurologic illness before HBAT administration, 
which could not be evaluated or assessed further by chart abstraction.
Despite these limitations, our findings strongly suggest that HBAT is well-tolerated for 
patients with suspected or confirmed botulism and that early HBAT administration is more 
effective than later administration. While our data were collected from patients with sporadic 
or outbreak-related illnesses due to unintentional exposure, it is likely that our findings 
would still apply in the context of an intentional mass casualty event. For the individual 
botulism patient properly managed in an intensive care setting, the advantages of HBAT 
appear to outweigh potential risks. During a mass casualty event, early HBAT treatment may 
help lessen the population-level strain on limited healthcare resources by reducing the 
duration of hospitalization and intensive care required by individual patients. However, 
undesirable consequences arising from the rare risk of otherwise mild HBAT-related AEs 
may be magnified in these situations if supportive care resources are limited. Regardless of 
the context in which botulism occurs, our data further support the importance of maintaining 
clinical suspicion for this paralytic illness to help ensure that safe and effective management 
is implemented in a timely manner.
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Figure 1. 
Kaplan-Meier curves for duration of hospitalization, intensive care unit (ICU) stay, and 
mechanical ventilation after heptavalent botulinum antitoxin (HBAT) among botulism-
confirmed patients by timing of HBAT administration in relation to symptom onset (n=104). 
Three deaths during acute inpatient hospitalization were censored.
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Table 1
Demographic Characteristics of Patients Treated With Heptavalent Botulinum Antitoxina
Characteristic All Patients Treated With HBAT (n = 249) HBAT-Treated Patients With Confirmed Botulism (n = 104)
Median age (range) 46 y (10 d–88 y) 43 y (10 d–83 y)
Age group, y
 0 to <1b 1 (<1%) 1 (1%)
 1–9 8 (3%) 1 (1%)
 10–17 8 (3%) 4 (4%)
 18–29 35 (14%) 21 (20%)
 30–39 46 (19%) 21 (20%)
 40–49 42 (17%) 24 (23%)
 50–59 49 (20%) 14 (14%)
 60–69 36 (15%) 11 (11%)
 70–79 17 (7%) 6 (6%)
 ≥80 7 (3%) 1 (1%)
Sex
 Male 178 (72%) 84 (81%)
 Female 71 (29%) 20 (19%)
Ethnicity
 Hispanic/Latino 90 (36%) 38 (37%)
 Not Hispanic/Latino 110 (44%) 56 (54%)
 Not reported 49 (20%) 10 (10%)
Race
 White 139 (56%) 73 (70%)
 Alaska Native 14 (6%) 8 (8%)
 African American 14 (6%) 3 (3%)
 Asian 12 (5%) 5 (5%)
 Other 6 (2%) 4 (4%)
 Native American 3 (1%) 3 (3%)
 Not reported 61 (25%) 8 (8%)
Abbreviation: HBAT, heptavalent botulinum antitoxin.
a
The majority of patients were treated during the expanded access Investigational New Drug period from 2010–2013; 4 patients were treated 2008–
2009. Most patients were treated in the United States while 5 patients were treated in Mexico.
b
Infant botulism type F illness treated with HBAT because the licensed product for infant botulism treatment, BabyBIG® does not contain Anti-F 
activity.
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Table 2
Number of Physician-Reported Adverse Events Related to Treatment With Heptavalent Botulinum Antitoxin
Adverse Event
Events Among Adult 
Patients (n = 232), 
No. (%)
Events Among 
Pediatric Patients (n = 
17), No. (%)
No Events Among All 
Patients (N = 249), 
No. (%)
Nonserious adverse event
 Fever 8 (3%) 1 (6%) 9 (4%)
 Rash 4 (2%) 0 4 (2%)
 Chills 3 (1%) 0 3 (1%)
 Agitation/anxiety 2 (1%) 1 (6%) 3 (1%)
 Edema 2 (1%) 0 2 (1%)
 Hypertension/increased blood pressure 2 (1%) 0 2 (1%)
 Nausea 2 (1%) 0 2 (1%)
 Mild serum sicknessa 1 (<1%) 0 1 (<1%)
 Otherb 11 (5%) 1 (6%) 12 (5%)
 Total No. of nonserious adverse events 35 3 38
Serious adverse event
 Hemodynamic instability (bradycardia, tachycardia, 
asystole)c
0 1 (6%) 1 (<1%)
 Anaphylactic reaction 0 0 0
 Total No. of serious adverse events 0 1 1
Total number of adverse events 35 4 39
a
Reported as “self-limited serum sickness” 11 days after heptavalent botulinum antitoxin administration.
b
Bronchospasm, chest pressure, diaphoresis, erythema, increased respiratory rate, “jitteriness,” leukocytosis, mild hypotension, tachycardia, urinary 
retention, and vomiting were each reported once each among adults and a complaint of “hurting all over” during infusion was reported for 1 
pediatric patient.
cA 10-year-old child experienced hemodynamic instability characterized by bradycardia, tachycardia, and asystole.
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